Breaking News, Collaborations & Alliances

AtheroNova Ships API for Early Phase Trials

Clinical-grade material will be used for Russian tox studies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AtheroNova, Inc. has initiated the first shipment of AHRO-001 API to its R&D partner CardioNova, Ltd., for Phase I and II studies. The clinical-grade material will be used for toxicology studies conducted for Russian regulatory purposes.   “We are pleased to announce this first shipment, clearly a milestone for us in the development of AHRO-001 for use in upcoming human clinical studies,” said AtheroNova chief executive officer, Thomas Gardner. “This is the highest purity e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters